Satsuma Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John A. Kollins MBA
- Full Time Employees
- 25
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 400 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Sep 13, 2019
- CIK
- 0001692830
- Website
- satsumarx.com
- Similar Companies
- Business
- Satsuma Pharmaceuticals, Inc. is a development-stage biopharmaceutical company specializing in the development and commercialization of innovative therapeutic products for the acute treatment of migraine. Its primary product offering is STS101, a proprietary nasal powder formulation of dihydroergotamine mesylate (DHE) delivered through its SMART (Simple MucoAdhesive Release Technology) platform, designed to provide rapid and effective relief from migraine with or without aura in adults. This drug-device combination addresses unmet needs in migraine therapy by offering a non-oral, easy-to-use treatment option with improved self-administration consistency. Satsuma operates primarily in the United States and focuses on leveraging its drug-device expertise, particularly in inhalation delivery systems, with a portfolio that includes a patented delivery technology and a novel nasal powder formulation. Founded in 2016 and headquartered in Durham, North Carolina, Satsuma has built a team with extensive experience in drug development, manufacturing, and commercialization, particularly of combination drug-device products. A major strategic development for the company occurred in April 2023 when Shin Nippon Biomedical Laboratories, Ltd. (SNBL), a Japanese pharmaceutical company, completed a definitive acquisition of Satsuma Pharmaceuticals. This acquisition brought STS101 under SNBL’s global development and commercialization umbrella, combining Satsuma’s drug formulation with SNBL’s intranasal drug device technology. In 2025, Satsuma’s STS101 was approved by the U.S. Food and Drug Administration (FDA) as the first and only DHE nasal powder indicated for acute migraine treatment, solidifying the company's position in the migraine therapeutics market. The company and its parent SNBL have recently published positive Phase 3 clinical data supporting STS101's safety, efficacy, and patient satisfaction, reinforcing its role as a differentiated therapeutic option. Satsuma’s core product, STS101, marketed under the brand Atzumi™, represents its sole commercial product following clinical stage development. The company continuously engages in clinical research and regulatory activities to support product launch and expansion. Following the acquisition, Satsuma operates as a subsidiary under SNBL, focusing on migraine patients across the U.S. market and potentially leveraging SNBL’s international presence for further commercialization. The company does not currently have other products in its pipeline beyond STS101 and is pursuing commercialization and life cycle management of this key asset. Thus, Satsuma Pharmaceuticals focuses on innovative migraine therapeutics through proprietary nasal drug-device combinations with a key strategic transition following acquisition by SNBL and FDA approval of its lead product, STS101.
Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting
Best Penny Stocks To Buy Now? 7 Insider Picks In November
Penny Stocks To Buy: 7 Insider Picks For November 2022
Why Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today?
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights
Satsuma Pharmaceuticals to Present at SVB Leerink's CNS Forum
STSA Stock Price Increases Over 15% Pre-Market: Why It Happened
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths